Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
23010	Zanubrutinib	Brukinsa®	Zanubrutinib as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). The place in therapy for zanubrutinib, proposed by the Applicant, is narrower than the licensed population i.e.  as monotherapy for patients with CLL, who are treatment naïve and have del(17p) and/or TP53 mutations or for patients that have relapsed and/or refractory disease	Rapid Review Complete	20th October 2023